Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

about

Reversible covalent direct thrombin inhibitors

P2860

Q58803812-F1ADB449-9117-45F7-BF3E-B82DBE10F8E8

P2860

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

Item

http://www.wikidata.org/entity/Q39129273

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

@en

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

@nl

type

Item

label

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

@en

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

@nl

prefLabel

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

@en

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

@nl

P1476

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

@en

P2093

Hannah A Blair

http://www.w3.org/2001/XMLSchema#string

P2860

Warfarin reversal

Dabigatran versus warfarin in patients with atrial fibrillation

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data.

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.

The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.

Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.

P2888

s40265-017-0699-z

P304

331-344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-017-0699-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gillian M Keating

P577

2017-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28185082

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

about

P2860

P2860

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921